INNOVIVA, INC. Payments to Acquire Available-for-sale Securities
INNOVIVA, INC. (INVA) reported Payments to Acquire Available-for-sale Securities of $67.62 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-02-23
- INNOVIVA, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $25.88M, a 99.49% increase year-over-year.
- INNOVIVA, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $29.77M, a 30.28% increase year-over-year.
- INNOVIVA, INC. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $7.98M, a 81.84% decline year-over-year.
- INNOVIVA, INC. payments to acquire available-for-sale securities for the quarter ending 2017-03-31 was $3.99M, a 75.02% decline year-over-year.
- INNOVIVA, INC. payments to acquire available-for-sale securities for fiscal 2017 was $67.62M, a 29.35% decline from fiscal 2016.
- INNOVIVA, INC. payments to acquire available-for-sale securities for fiscal 2016 was $95.72M, a 10.63% increase from fiscal 2015.
- INNOVIVA, INC. payments to acquire available-for-sale securities for fiscal 2015 was $86.52M, a 68.75% decline from fiscal 2014.
- INNOVIVA, INC. payments to acquire available-for-sale securities for fiscal 2014 was $276.91M, a 32.53% decline from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $25.88M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $55.65M derived: sum of 2 quarters · filed 2018-02-23 | $63.63M derived: sum of 3 quarters · filed 2018-02-23 | $67.62M 10-K · filed 2018-02-23 |
| 2017-09-30 | $29.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $37.75M derived: sum of 2 quarters · filed 2017-11-03 | $41.74M 10-Q · filed 2017-11-03 | $54.72M derived: sum of 4 quarters · filed 2018-02-23 |
| 2017-06-30 | $7.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $11.97M 10-Q · filed 2017-08-08 | $24.94M derived: sum of 3 quarters · filed 2018-02-23 | $47.80M derived: sum of 4 quarters · filed 2018-02-23 |
| 2017-03-31 | $3.99M 10-Q · filed 2017-05-05 | $16.96M derived: sum of 2 quarters · filed 2018-02-23 | $39.82M derived: sum of 3 quarters · filed 2018-02-23 | $83.73M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-12-31 | $12.97M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $35.83M derived: sum of 2 quarters · filed 2018-02-23 | $79.74M derived: sum of 3 quarters · filed 2018-02-23 | $95.72M 10-K · filed 2018-02-23 |
| 2016-09-30 | $22.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $66.77M derived: sum of 2 quarters · filed 2017-11-03 | $82.75M 10-Q · filed 2017-11-03 | $82.75M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | $43.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $59.89M 10-Q · filed 2017-08-08 | $59.89M derived: sum of 3 quarters · filed 2018-02-23 | $137.96M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | $15.98M 10-Q · filed 2017-05-05 | $15.98M derived: sum of 2 quarters · filed 2018-02-23 | $94.04M derived: sum of 3 quarters · filed 2018-02-23 | $94.04M derived: sum of 4 quarters · filed 2018-02-23 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $78.07M derived: sum of 2 quarters · filed 2018-02-23 | $78.07M derived: sum of 3 quarters · filed 2018-02-23 | $86.52M 10-K · filed 2018-02-23 |
| 2015-09-30 | $78.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $78.07M derived: sum of 2 quarters · filed 2016-11-03 | $86.52M 10-Q · filed 2016-11-03 | $134.54M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $8.46M 10-Q · filed 2016-08-04 | $56.47M derived: sum of 3 quarters · filed 2017-02-28 | $142.51M derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $8.46M 10-Q · filed 2016-05-05 | $56.47M derived: sum of 2 quarters · filed 2017-02-28 | $142.51M derived: sum of 3 quarters · filed 2017-02-28 | $228.72M derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $48.02M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $134.05M derived: sum of 2 quarters · filed 2017-02-28 | $220.26M derived: sum of 3 quarters · filed 2017-02-28 | $276.91M 10-K · filed 2017-02-28 |
| 2014-09-30 | $86.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $172.25M derived: sum of 2 quarters · filed 2015-11-05 | $228.90M 10-Q · filed 2015-11-05 | $284.72M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-30 | $86.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $142.86M 10-Q · filed 2015-08-06 | $198.69M derived: sum of 3 quarters · filed 2016-02-24 | $341.47M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-31 | $56.65M 10-Q · filed 2015-05-08 | $112.47M derived: sum of 2 quarters · filed 2016-02-24 | $255.26M derived: sum of 3 quarters · filed 2016-02-24 | $362.93M derived: sum of 4 quarters · filed 2016-02-24 |
| 2013-12-31 | $55.82M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $198.61M derived: sum of 2 quarters · filed 2016-02-24 | $306.28M derived: sum of 3 quarters · filed 2016-02-24 | $410.41M 10-K · filed 2016-02-24 |
| 2013-09-30 | $142.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $250.46M derived: sum of 2 quarters · filed 2014-11-04 | $354.58M 10-Q · filed 2014-11-04 | $408.64M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $107.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $211.80M 10-Q · filed 2014-08-07 | $265.86M derived: sum of 3 quarters · filed 2015-02-27 | $356.82M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $104.13M 10-Q · filed 2014-05-07 | $158.18M derived: sum of 2 quarters · filed 2015-02-27 | $249.15M derived: sum of 3 quarters · filed 2015-02-27 | $398.94M derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $54.06M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $145.03M derived: sum of 2 quarters · filed 2015-02-27 | $294.81M derived: sum of 3 quarters · filed 2015-02-27 | $330.48M 10-K · filed 2015-02-27 |
| 2012-09-30 | $90.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | $240.75M derived: sum of 2 quarters · filed 2013-11-01 | $276.43M 10-Q · filed 2013-11-01 | $346.70M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | $149.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $185.46M 10-Q · filed 2013-08-01 | $255.74M derived: sum of 3 quarters · filed 2014-03-03 | $310.70M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $35.67M 10-Q · filed 2013-05-01 | $105.95M derived: sum of 2 quarters · filed 2014-03-03 | $160.91M derived: sum of 3 quarters · filed 2014-03-03 | |
| 2011-12-31 | $70.28M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $125.24M derived: sum of 2 quarters · filed 2014-03-03 | $301.56M 10-K · filed 2014-03-03 | |
| 2011-09-30 | $54.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | $231.28M 10-Q · filed 2012-10-31 | ||
| 2011-06-30 | $176.32M 10-Q · filed 2012-08-01 | |||
| 2010-12-31 | $183.90M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |